Nuvation Bio Inc (NUVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nuvation Bio Inc (NUVB) Stock Forecast
Analysts expect Nuvation Bio (NUVB) to earn -$0.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $203.17M. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.85, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 23.1% |
| Buy | 9 | 69.2% |
| Hold | 1 | 7.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 23.5%.
- Fiscal year ending Dec 31, 2026
- -$0.29
- EPS consensus, revenue $203.17M
- Fiscal year ending Dec 31, 2027
- -$0.08
- EPS consensus, revenue $250.89M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.29 | -$0.30 to -$0.28 | 2 | $203.17M | $190.60M to $236.43M | 13 |
| Dec 31, 2027 | -$0.08 | -$0.16 to $0.00 | 2 | $250.89M | $199.10M to $332.43M | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.11 for the quarter ending Dec 31, 2026 to -$0.06 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.11 | -$0.14 to -$0.03 | 15 | $45.16M | $32.24M to $79.80M | 15 |
| Mar 31, 2027 | -$0.06 | -$0.12 to $0.00 | 4 | $56.73M | $36.60M to $80.00M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.29 | -$0.29 | -$0.29 | -$0.29 | -$0.29 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.08 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | N/A |
| Quarter ending Mar 31, 2027 | -$0.06 | -$0.03 | -$0.04 | -$0.03 | -$0.03 | N/A |
Frequently Asked Questions About NUVB
What is the NUVB stock forecast?
Consensus analyst estimates put Nuvation Bio's EPS at -$0.29 for the fiscal year ending Dec 31, 2026, on revenue of $203.17M. The consensus rating from 13 analysts is Buy.
How do analysts rate NUVB stock?
Of 13 analysts covering Nuvation Bio, 3 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NUVB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.29, with estimates from -$0.30 to -$0.28 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.16 to $0.00 from 2 analysts.
What revenue do analysts expect from Nuvation Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $203.17M, with estimates from $190.60M to $236.43M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $250.89M, with estimates from $199.10M to $332.43M.
How many analysts cover NUVB?
13 analysts rate Nuvation Bio stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NUVB pages: Overview, Earnings, Forecast, Financials, Competitors